灵敏可靠的ELISA试剂盒，用于检测血浆、血清和尿液样本中的缓激肽

缓激肽（Bradykinin）于1949年被发现，由血浆中的球蛋白前体在蛋白酶的作用下生成。它的名字表明它会促使肠道缓慢运动。早在1909年，人们就注意到在尿液中发现的物质（后来被确定为激肽）具有降压作用。激肽是血管舒张、血管通透性、NO 释放和花生四烯酸动员的效应物。它们是血压、肾功能和心脏功能的重要调节因子，并且还参与炎症反应。

缓激肽是通过血液中激肽释放酶系统的作用（与凝血级联有关）从血球蛋白激肽原HK 产生的，但也可以在其他组织和器官中产生。除激肽释放酶外，其他蛋白酶如纤溶酶也可释放缓激肽。几种肽酶可以降解激肽，包括血管紧张素转化酶(ACE)，这是一种可将血管紧张素 I 转化为血管紧张素 II 并破坏缓激肽的金属蛋白酶。血浆缓激肽迅速降解为较小的稳定肽(BK1-5)形式。

Enzo Life Sciences /欣博盛生物 的缓激肽（Bradykinin）ELISA试剂盒是一种竞争比色法免疫检测试剂盒，可在3小时内得出结果。欣博盛生物作为Enzo Life Sciences授权中国一级代理，可提供该产品，欢迎咨询。

产品特点

◆ 灵敏、可靠地检测低至 24.8 pg/ml 的缓激肽

◆ 仅需3小时即可得到多达 41 个样本（带复孔）的实验结果

◆ 动态范围宽，可轻松量化高表达水平和低表达水平的缓激肽

◆ 易于使用的液体颜色编码试剂，可减少错误

  

产品信息

产品货号	ADI-900-206
产品名称	Bradykinin ELISA kit（缓激肽ELISA试剂盒）/欣博盛生物
规格	96 wells
灵敏度	24.8 pg/ml
检测范围	11.7-30,000 pg/ml
应用	ELISA, Colorimetric detection
检测波长	450 nm
适用样本类型	血浆，血清和尿液样本
适用种属	不限种属
交叉反应	Bradykinin (100%) Lys-Bradykinin (Kallidin) (100%)  and Les-des-Arg9-Bradykinin (<1%), BK1-5 stable degradion product (<0.1%)
使用/稳定性	Store all components at +4ºC, except Standard at -20ºC
运输温度	Blue Ice
短期保存温度	-20°C
长期保存温度	-20°C
试剂盒组分	Microtiter Plate, Conjugate, Antibody, Assay Buffer 16, Wash  Buffer Concentrate, Standard, TMB Substrate, Stop Solution 2, Streptavidin-HRP

标准曲线示例

部分产品引用文献

Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19: C.P. Martens, et al.; EBioMedicine 83, 104195 (2022)

Activation of angiotensin type 2 receptor attenuates testosterone-induced hypertension and uterine vascular resistance in pregnant rats: J.S. Mishra & S. Kumar; Biol. Reprod. 2021, ioab051 (2021)

gC1qR Antibody Can Modulate Endothelial Cell Permeability in Angioedema: M. Fandaros, et al.; Inflammation 1007, 10753 (2021)

Plasma contact factors as novel biomarkers for diagnosing Alzheimer's disease: J. Park, et al.; Biomark. Res. 9, 5 (2021)

The Expression of RAAS Key Receptors, Agtr2 and Bdkrb1, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome: M. Punapart, et al.; Genes (Basel) 12, 1717 (2021)

An antibody against HK blocks Alzheimer's disease peptide β-amyloid-induced bradykinin release in human plasma: Z.L. Chen, et al.; PNAS 116, 22921 (2019)

Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2: Y. Zhou, et al.; Int. J. Oncol. 55, 131 (2019)

Post-translational modifications of eNOS augment nitric oxide availability and facilitates hypoxia adaptation in Ladakhi women: Pooja, et al.; Nitric Oxide 78, 103 (2018)

Protocols to assess coagulation following in vitro infection with hemorrhagic fever viruses: M.L. Tursiella, et al.; Methods Mol. Biol. 1604, 405 (2018)

Intestinal ischemic preconditioning ameliorates hepatic ischemia/reperfusion injury in rats: role of heme oxygenase 1 in the second window of protection: S. Kageyama, et al.; Liver Transpl. 21, 112 (2015)

Comparative effects of a novel angiotensin-converting enzyme inhibitor versus captopril on plasma angiotensins after myocardial infarction: J. Flores-Monroy, et al.; Pharmacology 94, 21 (2014)

High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis: A. Yang, et al.; J. Immunol. 192, 4398 (2014)